AU2001233917A1 - Bcmp-7 as marker for diagnosis of breast cancer - Google Patents

Bcmp-7 as marker for diagnosis of breast cancer

Info

Publication number
AU2001233917A1
AU2001233917A1 AU2001233917A AU3391701A AU2001233917A1 AU 2001233917 A1 AU2001233917 A1 AU 2001233917A1 AU 2001233917 A AU2001233917 A AU 2001233917A AU 3391701 A AU3391701 A AU 3391701A AU 2001233917 A1 AU2001233917 A1 AU 2001233917A1
Authority
AU
Australia
Prior art keywords
bcmp
breast cancer
diagnosis
marker
immunospecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233917A
Inventor
Robert Simon Boyd
Alasdair Craig Stamps
Jonathan Alexander Terrett
Kerry Louise Tyson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2001233917A1 publication Critical patent/AU2001233917A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The present invention provides the use of a protein found in breast cancer cell membranes, known as BCMP 11, in the diagnosis, screening, treatment and prophylaxis of breast cancer or prostate cancer, as well as compositions comprising BCMP 11, including vaccines and antibodies that are immunospecific for BCMP 11.
AU2001233917A 2000-02-25 2001-02-21 Bcmp-7 as marker for diagnosis of breast cancer Abandoned AU2001233917A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0004576 2000-02-25
GBGB0004576.5A GB0004576D0 (en) 2000-02-25 2000-02-25 Proteins
PCT/GB2001/000734 WO2001063290A1 (en) 2000-02-25 2001-02-21 Bcmp-7 as marker for diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
AU2001233917A1 true AU2001233917A1 (en) 2001-09-03

Family

ID=9886470

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001235761A Abandoned AU2001235761A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-11 as marker
AU2001233917A Abandoned AU2001233917A1 (en) 2000-02-25 2001-02-21 Bcmp-7 as marker for diagnosis of breast cancer
AU2001233912A Abandoned AU2001233912A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-81 as marker

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001235761A Abandoned AU2001235761A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-11 as marker

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001233912A Abandoned AU2001233912A1 (en) 2000-02-25 2001-02-21 Diagnosis of breast cancer using bcmp-81 as marker

Country Status (8)

Country Link
US (2) US20020111303A1 (en)
EP (2) EP1257827A1 (en)
AT (1) ATE306668T1 (en)
AU (3) AU2001235761A1 (en)
DE (1) DE60113968T2 (en)
ES (1) ES2249410T3 (en)
GB (1) GB0004576D0 (en)
WO (3) WO2001063289A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US7608696B2 (en) * 2001-10-26 2009-10-27 Dana-Farber Cancer Institute, Inc. IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
AU2003209459A1 (en) * 2002-03-06 2003-09-16 Hybrigenics Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
EP1576007A2 (en) * 2002-12-23 2005-09-21 Ingenium Pharmaceuticals AG Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders
CA2527571A1 (en) 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20050277167A1 (en) * 2004-03-11 2005-12-15 Bachinger Hans P Prolyl 3-hydroxylases
GB0616929D0 (en) * 2006-08-26 2006-10-04 Univ Liverpool Antibodies, assays and hybridomas
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003132A1 (en) * 1984-01-06 1985-07-18 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
EP0929575A4 (en) * 1996-08-23 2004-09-08 Human Genome Sciences Inc Novel human growth factors
WO2000053755A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
WO1999018202A2 (en) * 1997-10-08 1999-04-15 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND cDNAs ENCODING THESE PROTEINS
DE19817557A1 (en) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences from ovarian tumor tissue
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3752700A (en) * 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators

Also Published As

Publication number Publication date
AU2001235761A1 (en) 2001-09-03
EP1259814A1 (en) 2002-11-27
DE60113968T2 (en) 2006-06-22
DE60113968D1 (en) 2006-02-23
ATE306668T1 (en) 2005-10-15
EP1259814B1 (en) 2005-10-12
GB0004576D0 (en) 2000-04-19
US20020111303A1 (en) 2002-08-15
US20030017456A1 (en) 2003-01-23
AU2001233912A1 (en) 2001-09-03
EP1257827A1 (en) 2002-11-20
WO2001063290A1 (en) 2001-08-30
ES2249410T3 (en) 2006-04-01
WO2001063288A1 (en) 2001-08-30
WO2001063289A1 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
YU9404A (en) Peptide-based multimeric targeted contrast agents
YU37304A (en) Specific binding agents of human angiopoietin-2
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2003087831A3 (en) Proteins involved in breast cancer
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
HK1040983A1 (en) Quinones for treatment of diseases.
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
MXPA02011563A (en) Compositions and methods for the therapy and diagnosis of breast cancer.
TR200200278T2 (en) Calcilitic compositions
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
AU2001280443A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
WO2002102849A3 (en) Bcmp-101, a cancer associated protein
TW200635953A (en) Specific binding agents of human angiopoietin-2